BMO Capital analyst Alex Arfaei maintained a Hold rating on Merck & Company (MRK) today. The company’s shares closed on Friday at $79.81, close to its 52-week high of $80.19.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 9.1% and a 72.8% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Eli Lilly & Co, and Bristol Myers.
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $83.25.
See today’s analyst top recommended stocks >>
Based on Merck & Company’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $11 billion and net profit of $1.83 billion. In comparison, last year the company earned revenue of $10.45 billion and had a GAAP net loss of $1.05 billion.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
